Beneficient closes $7.44m GP primary deal with Quartus AI Fund II

Beneficient (NASDAQ: BENF), a Dallas-based technology-enabled alternative asset platform, has closed a $7.44 million primary capital commitment in Quartus AI Fund II LP, a growth-stage AI and technology fund managed by New York firm Quartus Capital Partners. The consideration was settled in Beneficient's Resettable Convertible Preferred Stock, convertible into Class A common shares at the holder's election, rather than in cash.

The deal is the second GP primary capital transaction between the two firms this year, and the commitment is structured to scale up to $26.25 million if Quartus AI Fund II reaches its target capitalisation of $150 million. Beneficient says the transaction adds approximately $7.44 million to its tangible book value attributable to public company stockholders, and increases collateral for its ExAlt loan portfolio by a similar amount. Year to date, the company's GP primary capital programme has contributed approximately $17.2 million in aggregate tangible book value on the same basis.

The deal

Quartus AI Fund II is targeting growth-stage companies that generate at least $5 million in commercial revenue and show meaningful further growth potential. The fund's sector sweep is broad, spanning HealthTech, EdTech, LegalTech, Logistics, and what Quartus terms "Physical AI", covering autonomous vehicles, robotics and other systems that interact with the physical world, alongside safety and security applications. The strategy reflects a broader market shift toward later-stage AI bets, where investors can point to existing revenue rather than purely pre-commercial research.

Chief executive James Silk said the company was "pleased to expand our relationship with Quartus" and that the GP Primary Commitment Programme gives Beneficient "a pathway to participate in that growth through exposure to differentiated AI-focused private investment funds." The release notes that Beneficient views the programme as addressing up to $330 billion of potential demand from general partners seeking anchor commitments during fundraising.

Importantly, the transaction still requires stockholder approval for the underlying conversion of preferred stock into Class A shares. Beneficient said it will file preliminary and definitive proxy statements with the SEC.

Market context

Beneficient's GP Primary Commitment Programme occupies a niche corner of the alternative asset market, sitting between traditional fund-of-funds allocators and direct-lending platforms. Rather than deploying cash, it uses its own equity as currency to acquire fund interests, a structure that preserves liquidity while building a portfolio of alternative asset exposures. The model is unusual and carries execution risk: the tangible book value gains it reports are non-GAAP measures that depend heavily on the ultimate performance of underlying fund holdings.

The broader market for AI-focused growth-stage funds remains highly competitive. Institutional allocators, sovereign wealth funds, and large multi-strategy managers are all increasing exposure to AI venture and growth equity, which has pushed valuations for commercially mature AI companies well above historical norms. Quartus's focus on companies already clearing $5 million in revenue is a positioning choice that aims to reduce early-stage binary risk, though it does not eliminate valuation risk in a market where AI multiples remain elevated.

Beneficient's market capitalisation stood at approximately $50.6 million as of 10 July 2026, meaning the $7.44 million commitment represents a material portion of the company's public equity value. Investors will be watching for how the fund's NAV develops, whether Quartus AI Fund II reaches its $150 million target, and how the preferred stock conversion mechanics play out once stockholder approval is sought.